Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EPS (Weighted Average and Diluted) (2016 - 2025)

Coherus Oncology's EPS (Weighted Average and Diluted) history spans 10 years, with the latest figure at -$0.38 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 5.0% year-over-year to -$0.38; the TTM value through Dec 2025 reached -$1.56, up 0.64%, while the annual FY2025 figure was -$1.56, 17.02% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.38 at Coherus Oncology, down from -$0.3 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.09 in Q3 2024 and bottomed at -$2.37 in Q1 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.49 (2021), against an average of -$0.66.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 636.36% in 2021 before it surged 75.68% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.59 in 2021, then dropped by 28.81% to -$0.76 in 2022, then grew by 2.63% to -$0.74 in 2023, then skyrocketed by 45.95% to -$0.4 in 2024, then rose by 5.0% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's EPS (Weighted Average and Diluted) are -$0.38 (Q4 2025), -$0.3 (Q3 2025), and -$0.39 (Q2 2025).